About the Company
Philip Low (born 1979) is a Canadian inventor, computational neuroscientist, and mathematician. He is the chairman, CEO and founder of NeuroVigil, a neurotechnology company. He is the author of the Cambridge Declaration on Consciousness; his research is focused on the development of technical means to decipher human brain waves. MIT Technology Review recognized him as one of its 2010 "35 Under 35" outstanding innovators.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Vigil Neuroscience, Inc.
Why Vigil Neuroscience, Inc. (VIGL) is Skyrocketing So Far in 2025
We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Vigil Neuroscience, Inc. (NASDAQ:VIGL ...
Vigil Neuroscience Inc: Potential for Accelerated Approval and Proof of ...
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain ...
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial ...
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Mar. 26, 2024 7:05 AM ET Vigil Neuroscience, Inc. (VIGL) ...
Vigil Neuroscience Inc.: A Cautious Sell Amid Development Uncertainties ...
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain ...
Vigil Neuroscience, Inc. Reports Positive Phase 1 Data for VG ... - Nasdaq
Vigil Neuroscience, Inc. announced promising outcomes from a Phase 1 clinical trial of VG-3927, a potential treatment for Alzheimer’s Disease, and intends to commence a Phase 2 trial in the ...
Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming ...
WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment ...
Vigil Neuroscience, Inc. (NASDAQ:VIGL) has caught the attention of ...
We can see that insiders own shares in Vigil Neuroscience, Inc.. It has a market capitalization of just US$153m, and insiders have US$1.6m worth of shares, in their own names.
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
Stay ahead of market moves. Get critical insights with Premium » Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days Mar. 12, 2024 7:05 AM ET Vigil Neuroscience, Inc. (VIGL) ...
Press Release: Sanofi to acquire Vigil Neuroscience, Inc ... - Nasdaq
Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’ s disease to the neurology pipeline. Paris, May 22, 2025. Sanofi announced today that it has ...
Vigil Neuroscience, Inc.: Vigil Neuroscience Reports First Quarter 2025 ...
Net Loss: Net loss from operations for the first quarter ended March 31, 2025 were $22.4 million, compared to $19.9 million for the same period in 2024. About Vigil Neuroscience ...
Vigil Neuroscience Inc Merger and Leadership Changes
Detailed price information for Vigil Neuroscience Inc (VIGL-Q) from The Globe and Mail including charting and trades.
Similar Companies
Loading the latest forecasts...